Miist Therapeutics

Miist Therapeutics is pioneering an inhaled microparticle drug delivery platform to treat acute conditions with an onset of action measured in seconds, not hours. Its lead program, MST-02 for migraine, is preparing for Phase 1/2 clinical trials, with a pipeline planned for other acute indications. The company, which raised a $7M funding round, leverages a novel approach to aerosol generation to create rapidly absorbed particles, positioning itself to address a significant unmet need for fast-acting therapies in multi-billion dollar markets.

Novel inhaled microparticle platform designed for ultra-rapid systemic drug delivery. Particles are engineered for fast absorption across the alveolar membrane, achieving peak plasma levels in <30 seconds. Platform uses vibration-based (not heat) nebulization to produce sterile aqueous particles.

Competes against established oral triptans/gepants and newer injectable CGRP inhibitors for migraine, which still have onset times of minutes to hours. Other companies are exploring non-oral routes (e.g., intranasal, sublingual), but Miist's claim of 30-second systemic onset, if validated, would be a key differentiator. Competitors include large pharma and specialty pharma with acute care portfolios.